Nutrien (NTR) News Today

Nutrien Ltd. (NYSE: NTR) shares have increased, with the most likely support coming from a broadly more optimistic earnings outlook from Zacks Research and continued investor interest in the company’s dividend.

• Positive Sentiment: Zacks Research raised its FY2027 EPS estimate to $4.38 from $3.66, a substantial improvement that suggests stronger expected profitability. The firm also lifted estimates for Q2 2027, Q4 2027, FY2026, FY2028, Q1 2027, Q3 2027, Q4 2026 and Q2 2028. Collectively, the revisions point to improving longer-term earnings expectations.
• Positive Sentiment: An investor article emphasizes the appeal of not missing another year of Nutrien’s dividend income, which may reinforce the stock’s attraction to income-oriented investors. You’ve Already Missed a Year of Dividends: Here’s Why I Wouldn’t Miss Another
• Neutral Sentiment: Nutrien’s estimated current-year EPS remains below the broader consensus at $4.71 versus $4.95, while FY2027 and FY2028 estimates are $4.38 and $4.23, respectively. This indicates improving expectations but not an across-the-board bullish outlook.
• Negative Sentiment: Zacks Research reduced its Q3 2026 EPS estimate to $0.78 from $0.92 and its Q1 2028 estimate to $0.63 from $0.76. These cuts signal potential near-term earnings pressure and could limit the stock’s upside.

Overall, the positive revisions—especially the large increase to FY2027 earnings—appear to outweigh the isolated quarterly downgrades. Investors should still monitor fertilizer pricing, agricultural demand and Nutrien’s ability to convert improved earnings expectations into actual results; the company’s latest quarterly EPS already came in slightly below analysts’ estimates.